BIIB vs DYN
BIIB: Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease. DYN: Dyne Therapeutics is a clinical-stage biotechnology company leveraging its proprietary FORCE platform to develop targeted therapies for serious, life-threatening muscle diseases.
Side-by-side fundamentals
| Metric | BIIB | DYN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $197.74 | $23.21 | |
| Market cap as of 2026-07-23 | $29.8B | $3.8B | |
| P/E as of 2026-07-23 | 21.75 | n/a | |
| PEG as of 2026-07-23 | 10.24 | n/a | |
| Net margin as of 2026-07-23 | +13.8% | n/a | |
| Gross margin as of 2026-07-23 | +75.5% | n/a | |
| Operating margin as of 2026-07-23 | +17.5% | n/a | |
| ROE as of 2026-07-23 | +7.5% | -58.3% | BIIB higher |
| ROA as of 2026-07-23 | +4.7% | -46.8% | BIIB higher |
| Debt / equity as of 2026-07-23 | 0.34 | 0.18 | DYN lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.9% | n/a | |
| Beta as of 2026-07-23 | 0.16 | 1.11 | |
| 1-year return as of 2026-07-22 close | +54.7% | +159.9% | DYN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.